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Abstract 
 
Recombinant methionyl human leptin (r-metHuLeptin) was first used as a 
replacement therapy in patients bearing inactivating mutations in the leptin gene. In 
this indication, it was shown since 1999 to be very efficient in inducing a dramatic 
weight loss in rare children and adults with severe obesity due to the lack of leptin. 
These first clinical trials clearly showed that r-metHuLeptin acted centrally to reduce 
food intake, inducing loss of fat mass, and to correct metabolic alterations, immune 
and neuro-endocrine defects. A few years later, r-metHuLeptin was also shown to 
reverse the metabolic complications associated with lipodystrophic syndromes, due 
to primary defects in fat storage, which induce leptin deficiency. The beneficial 
effects, which could be mediated by central and/or peripheral mechanisms, are 
thought to mainly involve the lowering effects of leptin on ectopic lipid storage, in 
particular in liver and muscles, reducing insulin resistance. Interestingly, r-
metHuLeptin therapy also reversed the hypothalamic-pituitary-gonadal axis 
dysfunctions associated with hypothalamic amenorrhea. 
However, if r-metHuLeptin treatment has been shown to be dramatically efficient in 
leptin deficient states, its very limited effect in inducing weight loss in common obese 
patients revealed that, in patients with adequate leptin secretion, mechanisms of 
leptin resistance and leptin tolerance prevent r-metHuLeptin from inducing any 
additional effects. 
This review will present the current data about the effects of r-metHuLeptin therapy in 
humans, and discuss the recent perspectives of this therapy in new indications. 
Introduction 
 
The discovery of leptin in 1994 [1] rapidly allowed the production of r-metHuLeptin 
(Amgen, Thousand Oaks, CA, USA then Amylin, San Diego, CA, USA), a 
recombinant analog of human leptin composed by the 146 aminoacids of mature  
human leptin with an additional methionyl residue at the N-terminal end of the 
recombinant protein. R-metHuLeptin is the only pharmaceutical form of leptin at 
present. An efficient replacement therapy using recombinant methionyl human leptin 
(r-metHuLeptin), in rare patients with primary leptin deficiency due to inactivating 
mutations in the leptin gene [2] or to lipodystrophic syndromes [3]. Beside the 
treatment of these rare conditions, r-metHuLeptin also generated great hopes for the 
treatment of common obesity, but clinical trials using pharmacological doses of r-
metHuLeptin showed a very limited effect in inducing weight loss in most of obese 
patients [4]. Since then, the better understanding of leptin involvement in metabolic 
regulations allowed to consider new indications for the use of r-metHuLeptin as a 
therapeutic agent, alone or in combination. In addition to its major role in the 
regulation of energy homeostasis and cellular triglyceride storage, leptin also 
appeared as a regulator of endocrine and immune functions.  
 
 
1- Replacement therapy with r-metHuLeptin  
 
1.1 Leptin deficiency syndromes linked to inactivating mutations in the leptin gene 
 
Patients with congenital leptin deficiency due to inactivating homozygous mutations 
in the leptin gene are mainly characterized by a very severe obesity with marked 
hyperphagia [5]. Leptin replacement was shown in 1995 to induce dramatic weight 
loss in ob/ob mice [6,7], and the first results of r-metHuLeptin therapy in humans with 
congenital leptin deficiency were reported in 1999 [2]. 
 
R-metHuLeptin was administrated in various doses. In affected children from the first 
reported family, r-metHuLeptin therapy has been initially designed to produce plasma 
leptin levels at only 10% of those predicted by height and weight (i.e., approximately 
0.028 mg/kg of lean body mass, administrated subcutaneously once daily at 8 a.m.) 
[2]. However, if the clinical response was not sufficient, r-metHuLeptin doses were 
increased to achieve 20 to 150% of the predicted leptin concentration [8]. In three 
adults from another family, r-metHuLeptin therapy started at doses of 0.02 to 0.04 
mg/kg/d through a once daily injection in the evening, and doses were subsequently 
adjusted, on the basis of the clinical responses, to 0.01 to 0.04 mg/kg/d (0.3 to 3.6 
mg/d) [9-11].  
 
In these patients, r-metHuLeptin reduced food intake via neural circuits that diminish 
the perception of food reward and enhance the response to satiety signals [12-14], 
leading to a sustained loss of weight, mainly due to the loss of fat mass, both in 
children [2,15] and in adults [9]. In contrast to other situations of weight loss, the 
leptin replacement-induced reduction of fat mass was not associated with a decrease 
in basal metabolic rate or in fat oxidation [16].  
 
Altered glucose and lipid homeostasis linked to severe obesity were also reversed 
after r-metHuLeptin therapy [8,9,15]. Insulin resistance, as assessed by 
hyperinsulinemia, decreased in all patients, in parallel with the gradual loss of fat 
mass, and an adult woman with diabetes achieved normal HbA1c levels after r-
metHuLeptin therapy, without any other antidiabetic agent. Metabolic investigations, 
using standardized meal tests, have shown that r-metHuLeptin acutely increases 
hepatic extraction of insulin. However, a long-term (24 months) therapy resulted in a 
2-fold decrease in insulin secretion and delivery, with a 10-fold increase in insulin 
sensitivity [17]. Although the pathophysiological mechanisms were not fully 
understood, a short interruption in the treatment, in the context of rapid weight gain, 
has been shown to further increase insulin sensitivity in genetically leptin-deficient 
adults [18]. In accordance, adiponectin plasma levels increased during r-metHuLeptin 
therapy, but were even higher after a 7 week-interruption period [11]. Regarding lipid 
profile, serum LDL-cholesterol and triglycerides decreased while HDL-cholesterol 
increased under r-metHuLeptin treatment [8,9,15]. 
 
Complete leptin deficiency is also associated with several neuro-endocrine defects. 
Hypogonadotropic hypogonadism is a common feature in congenital leptin 
deficiency, although spontaneous puberty occurred in some patients. r-metHuLeptin 
therapy led to normal maturation of the hypothalamic-pituitary reproductive axis in 
adults [9], and allowed appropriately timed pubertal development in treated children 
[8]. R-metHuLeptin administration did not cause precocious activation of the 
hypothalamic-pituitary gonadal axis in treated children, showing that leptin acts as a 
permissive factor for the development of puberty. In addition, the physiological 
synchronized circadian rhythmicity of leptin and thyrotropin secretion is impaired in 
leptin-deficient subjects [19], and central hypothyroidism has been diagnosed in 
some, but not all cases of congenital leptin deficiency [8,15,20]. R-metHuLeptin 
therapy has improved thyroid function tests in affected patients [8,15]. Although the 
hypothalamic-pituitary adrenal axis does not seem to be severely affected in these 
patients, it has been observed that r-metHuLeptin therapy improved the dynamics of 
cortisol secretion [9]. Growth was not significantly impaired in untreated affected 
children, and age-related insulin-like growth factor (IGF)-1 levels were in the normal 
ranges in all patients [8,9]. IGF binding protein (IGFBP)-1 levels were low at baseline, 
and increased during r-metHuLeptin therapy, but this could be secondary to weight 
loss and/or decreased insulinemia [9]. Serum IGFBP-2 was also increased by r-
metHuLeptin therapy, which could participate in the improvement of hepatic insulin 
sensitivity [21]. 
 
CD4+ T cell lymphopenia and hyporesponsiveness, which are observed in congenital 
leptin deficiency, were dramatically improved by r-metHuLeptin therapy [8,9,15]. The 
secretion of interferon !, a Th1 pro-inflammatory cytokine, which was completely 
suppressed in non-treated patients,  was significantly increased. R-metHuLeptin also 
increased the secretion of Th2/regulatory cytokines such as interleukin 4 and 10. In 
addition, under r-metHuLeptin treatment, basal oversecretion of transforming growth 
factor " decreased to normal levels [8]. Clinically, the improvement in asthma 
symptoms and the decrease of recurrent infectious episodes under r-metHuLeptin 
therapy could probably be related, at least partially, to this switch from a predominant 
Th2 to a Th1 cytokine response [15]. However, this immune reconstitution could also 
enhance the production of antibodies to r-metHuLeptin, which developed in all 
patients after about 6 weeks of treatment, and were capable of transient neutralizing 
leptin activity [8].   
 
Bone mineral density was not shown to be significantly altered in patients with 
congenital leptin deficiency, both before and after r-metHuLeptin treatment, although 
one of the adult patients had osteoporosis at baseline, possibly secondary to 
hypogonadism [10].  
 
A total of 20 patients with congenital leptin deficiency due to distinct mutations in the 
leptin gene have been identified. Most of these patients are currently on r-
metHuLeptin therapy with remarkable beneficial effects on body composition and 
weight, endocrine functions and immunity [10]. Therefore, antibodies produced 
against r-metHuLeptin do not seem to induce any long-term significant inhibition of 
therapeutic activity.  
 
 
1.2 Lipodystrophic syndromes with leptin deficiency  
 
Monogenic and acquired forms of lipodystrophic syndromes are rare disorders 
associated with severe metabolic complications such as insulin resistant diabetes, 
marked hypertriglyceridemia and liver steatosis. In these diseases, fat has a very 
limited ability to store excess caloric intake as triglycerides, and also shows profound 
defects in its endocrine functions, including leptin deficiency. Triglycerides, fatty acids 
and their derivatives are ectopically stored in the liver and in cardiac and skeletal 
muscles, where they inhibit several insulin-stimulated signalling pathways. Recent 
advances in molecular genetics of lipodystrophic syndromes have pointed out that 
several primary defects in adipose lipid droplet formation, maintenance and 
metabolic regulation play an important role in their pathophysiology [22,23]. 
 
Several reports have described the sustained beneficial effects of r-metHuLeptin 
substitution in several different forms of lipodystrophic syndromes with severe 
metabolic complications. 
 
 
1.2.1 Genetic or acquired lipodystrophic syndromes (excluding HIV infection)  
 In lipoatrophic mice with a primary defect in adipocyte differentiation, which 
recapitulates the clinical and biological findings observed in human lipodystrophies, 
including defects in leptin secretion, treatment with low doses of recombinant leptin 
was able to restore insulin sensitivity, independently, at least partly, of caloric 
restriction [24]. In addition, transplantation of fat from control, but not from ob/ob 
leptin-deficient animals, was able to reverse the metabolic alterations [25], supporting 
the hypothesis that fat loss, and particularly fat loss-associated leptin deficiency, 
plays a major role in the metabolic complications of lipodystrophies. 
 
Subsequently, three open-label trials in patients with lipodystrophic syndromes 
associated with a severe leptin deficiency have shown that a short-term r-
metHuLeptin therapy, although it did not reverse the lipoatrophy itself, has important 
beneficial effects on glucose homeostasis and dyslipidemia, improving hepatic and 
muscular insulin resistance with a decrease in liver steatosis and muscle lipid content 
[3,26,27]. In the first study, r-metHuLeptin was administrated at increasing doses up 
to 0.08 mg/kg/d, in two daily subcutaneous injections, for four months, in nine women 
with congenital (n=5) or acquired (n=3) generalized lipodystrophic syndromes, and 
one woman with familial partial lipodystrophy [3]. R-metHuLeptin was well tolerated, 
but induced a major decrease in the daily caloric intake (on average, 2680 to 1600 
kcal/day) with a mean body weight loss of 3.6 kg. Fifty to 65% of the weight loss was 
attributed to the decrease in liver volume (which reached on average -28%). Resting 
metabolic rate also decreased, in contrast to what was observed in patients with 
inactivating mutations in the leptin gene [16]. Fasting triglycerides (mean at baseline, 
14 g/l) decreased by a mean 60%, and mean HbA1c in the eight patients with 
diabetes (9.1% at baseline) by 1.9 pt. The rate of glucose disappearance during an 
insulin tolerance test, which doubled after r-metHuLeptin therapy, indicated an 
improvement in whole-body insulin sensitivity. In accordance with results obtained in 
pair-feed lipodystrophic mice [24], serum triglycerides and insulin rapidly increased 
after treatment withdrawal, despite a constant food intake, in one patient [3], 
indicating that the metabolic effects of r-metHuLeptin were, at least partly, 
independent of caloric restriction. Using hyperinsulinemic euglycemic clamp with 
isotopes infusion and nuclear magnetic resonance spectrometry, Petersen et al [26] 
showed in three of these nine patients that r-metHuLeptin therapy improved the 
severe hepatic and muscular insulin resistance which characterized these patients: a 
fourfold increase in the rate of glucose infusion rate and a twofold decrease in 
hepatic glucose production were observed during the hyperinsulinemic euglycemic 
clamp. However, regarding the insulin resistance at the adipose tissue level, r-
metHuLeptin therapy did not significantly decrease the glycerol turnover. These 
metabolic changes were associated with a dramatic decrease in hepatic triglyceride 
content (-85%), and an approximately 30% reduction in intramyocellular triglyceride 
and fatty acylCoA contents [26]. These results were confirmed in three other patients 
by Simha et al [27]. 
 
These studies suggest that the beneficial metabolic effects of r-metHuLeptin therapy 
could be due predominantly due its anti-steatotic actions, previously observed in 
liver, islet cells, skeletal muscle and heart [28]. Indeed, accumulation of fatty-acid-
derived metabolites inhibits insulin signalling, causing insulin resistance in skeletal 
muscle and liver [29]. Interestingly, it has been shown that leptin, directly and/or 
through the sympathetic nervous system, activates adenosine monophosphate-
activated kinase (AMPK) in muscle, which in turn activates fatty acid oxidation 
[28,30]. However Petersen at al did not evidenced any alteration in the fasting 
respiratory quotient after r-metHuLeptin therapy in generalized lipoatrophic patients, 
and proposed that intrahepatic and intramyocellular lipid lowering effects were mostly 
mediated by a reduction in energy intake [26]. Another hypothesis, although not 
precisely investigated in patients, is that the repression of stearoyl-CoA desaturase-1 
by leptin could contribute to decreased lipid synthesis, explaining the antisteatotic 
effects of leptin in the liver [31,32]. It is still unknown if the therapeutic benefits of r-
metHuLeptin are due to its central and/or peripheral effects. 
 
Hyperphagia is one of the symptoms of lipodystrophic syndromes, probably due to 
low endogenous circulating levels of leptin, which are decreased in proportion to the 
reduced subcutaneous fat stores [33]. Studying eight subjects with congenital or 
acquired generalized, or partial lipoatrophy, Mc Duffie et al [34] clearly showed that a 
four-month r-metHuLeptin therapy, at doses up to 0.08 mg/kg/d, did not modified the 
relative macronutrient composition of consumed food, significantly increased by 
twofold the satiety time defined as the length of time subjects remained sated after 
ingestion of a standardized preload meal.  In addition, satiation, i.e the time to 
voluntary cessation of eating from a standardized meal after a 12-h fast, was 
decreased. Thus, eating behaviour induced by r-metHuLeptin therapy resulted in less 
caloric, shorter, more satiating meals and longer-lived satiety. This effect may be 
mediated at least in part through a decreased fasting ghrelin concentration, a peptide 
produced mainly by the stomach and implicated in the short-term control of hunger 
onset, which is increased at baseline in patients with lipodystrophies [34]. Of note, 
the unique patient with partial lipodystrophy investigated in this study experienced 
minor changes in satiety and satiation compared to patients with generalized 
lipoatrophy [34]. 
 
Other open-label studies have reported that metabolic improvements are sustained 
during long-term (12 months) r-metHuLeptin therapy with usual replacement doses in 
two [35] then fifteen [36] patients with generalized lipoatrophy, diabetes, and low 
leptin levels. In the study form Javor et al [36], weight loss was stabilized after four 
months of treatment, achieving a total of 4.4 kg on average (BMI decreasing from 
21.5 to 20 kg/m2), due to dramatic reduction of appetite whereas resting energy rate 
was decreased. Improvement of glycemic control (mean decrease in HbA1c of 1.9 pt) 
was obtained although most patients were able to either discontinue insulin therapy 
(6 of 9 patients), decrease mean insulin doses by a mean 65% (3 of 9 patients), or 
discontinue oral antidiabetic therapy (6 of 8 patients), due to euglycemia [36]. 
Important reductions were observed in triglycerides (from a mean 13.8 to 5.16 g/l), 
total and LDL-cholesterol (from a mean 2.84 to 1.67g/l, and 1.39 to 0.85 g/l, 
respectively) but HDL-cholesterol was unchanged. A progressive effect of r-
metHuLeptin was evidenced on liver volume (from a mean 3,663 to 2,190 cm3 after 
12 months of therapy), due to a decrease in steatosis, as proved in several patients 
by histological analysis [37], which also showed a reduction by a mean 60% of 
nonalcoholic steatohepatitis activity, although fibrosis was unchanged. 
One patient stopped the treatment after 8 months, due to worsening proteinuria with 
diagnosis of membranoproliferative glomerulonephritis [36]. However, considering 
the results obtained in the other 15 patients, a significant reduction in proteinuria and 
hyperfiltration was demonstrated [38], and confirmed in other studies [31,39] 
suggesting that r-metHuLeptin is not harmful for the kidney.  
One of the patients from this study, diagnosed with acquired generalized lipoatrophy, 
had diffuse lymphadenopathy at baseline, which aggravated during r-metHuLeptin 
treatment, although metabolic parameters improved. Histological analysis revealed 
the presence of a T-cell lymphoma, and the treatment was discontinued after 8 
months [36]. Another case of T cell lymphoma was diagnosed under r-metHuLeptin 
therapy in a patient with acquired lipodystrophy [31]. The responsibility of r-
metHuLeptin is far to be proven, and T cell lymphoma may occur in acquired 
lipoatrophies in the absence of such therapy [40]. However, r-metHuLeptin therapy 
should probably be avoided in patients with both acquired lipoatrophy and 
lymphadenopathy.  
Finally, in this long-term evaluation study of r-metHuLeptin replacement therapy, 
seven patients developed binding antibodies directed against leptin, but without 
evidence of neutralizing activity [36]. 
 
Long-term r-metHuLeptin-replacement therapy was subsequently reported in seven 
Japanese patients with generalized lipodystrophy [39] and confirmed the previous 
results depicted above. In addition, benefits on glucose and triglycerides levels were 
achieved as soon as 7 days after treatment initiation, despite the use of very low 
initial doses of r-metHuLeptin (0.01-0.02 mg/kg/d). Once-daily injection was sufficient 
to control metabolic homeostasis. Insulin secretion, assessed from insulin response 
during OGTT, was rapidly and dramatically improved in the two patients with 
acquired lipodystrophies, whereas it remains depressed in congenital generalized 
lipodystrophies due to seipin mutations or of unknown cause. Non neutralizing 
antileptin antibodies were detected in two patients [39]. 
 
Immune modulatory effects of r-metHuLeptin have been investigated by Oral et al 
using peripheral blood mononuclear cells (PBMC) from ten patients with 
lipodystrophic syndromes during a four to eight-month replacement therapy [41]. R-
metHuLeptin induced a significant increase in the absolute number of T lymphocytes, 
with a modest increase in activated (CD3+ CD25+) T cells. Stimulated TNF# 
production by patients’ PBMC, which was low at baseline, was normalized by the 
treatment. The authors did not note any changes in the biological markers of auto-
immunity during therapy. Whether r-metHuLeptin therapy could exacerbate 
autoimmune diseases, frequently associated with lipodystrophic syndromes, remains 
to be established. 
 
The precise impact of r-metHuLeptin therapy on body composition at short and long-
term (12 months) has been investigated in 14 lipodystrophic patients by Moran et al 
[42]. As previously observed, r-metHuLeptin therapy decreased calorie intake by 
approximately 45% and resting energy expenditure by about 11% at the four-month 
time point, but remained stable thereafter. The same trend was observed for weight 
(mean -3kg) and fat mass (mean -0.4 kg). In contrast to what was reported in 
patients with inactivating mutations in the leptin gene, r-metHuLeptin also decreased 
lean body mass (on average by 2.9 kg) by the fourth month of therapy, without any 
significance difference in the 4- to 12- month values. There was no change in bone 
mineral content or density, calcium, phosphorus, vitamin D, or markers of bone 
formation and resorption during r-metHuLeptin replacement, as previously observed 
by Simha et al in two women with generalized lipodystrophy [43]. Bone density was 
also unchanged for up to 36 months of r-metHuLeptin therapy in seven lipodystrophic 
patients studied by Ebihara et al [39]. 
 
These results have to be interpreted together with those regarding other endocrine 
changes. Indeed, a four-month r-metHuLeptin therapy in seven women with 
lipodystrophy has been shown to restore a normal response to growth hormone-
releasing hormone (GHRH) stimulation and to improve the hypothalamic-pituitary 
gonadal axis functions, with correction of the attenuated response of luteinizing 
hormone (LH) to LHRH. R-metHuLeptin also increased estradiol and decreased 
testosterone serum levels, and improved menstrual abnormalities, whereas thyroid 
and adrenal functions appeared normal at baseline and were unchanged [44]. The 
beneficial effect of r-metHuLeptin on the gonadal axis has been confirmed in ten, 
then 23 hypoleptinemic lipodystrophic women [45,46], the latter trial having used 
higher doses of r-metHuLeptin (up to 0.24 mg/kg/d, adapted to metabolic control) [46]. 
Most of the patients had polycystic ovary syndrome with menstrual irregularities at 
baseline, and almost all had recovered normal menses after therapy [46]. Serum 
testosterone decreased and sex-hormone binding globulin (SHBG) increased after 1 
yr of treatment, by about two-fold, although basal levels of gonadotropins and ovarian 
size were not significantly modified [45,46], in favour of a predominant role of higher 
insulin sensitivity in improved ovarian functions. However, a qualitative improvement 
in gonadotrophin pulsatility in response to r-metHuLeptin cannot be ruled out. In 
accordance with results from Javor et al [36], IGF1 levels significantly increased in 
response to 1 yr- therapy [45,46]. As observed in patients with primary congenital 
defects in leptin, r-metHuLeptin treatment did not induced LH secretion prior to 
appropriate pubertal timing, but had a permissive effect, which was evidenced by an 
increase in the LH response to LHRH in three adolescents [45]. 
 
R-metHuLeptin has also been administrated to children with congenital lipodystrophy 
and leptin deficiency, before the onset of diabetes [47]. Seven children (of 2.4 to 13.6 
years-old) were treated for four months as part of an open-label trial. R-metHuLeptin 
did not induced any significant changes in weight, fat mass or puberty status, but 
clearly reduced triglycerides level (by a mean 63%), liver volume (- 20.3%) and 
increased insulin sensitivity by 30%, through an increase in peripheral glucose 
uptake, as assessed by euglycemic hyperinsulinemic clamps [47]. However, in five of 
eight children treated for 28 months, a partial or total resistance to r-metHuLeptin 
therapy was evidenced, which was associated with the early appearance of binding 
antileptin antibodies, exhibiting an in vitro neutralizing activity in two patients [48]. 
 
The efficacy of r-metHuLeptin replacement therapy to improve metabolic alterations 
seems to depend on the clinical forms of lipodystrophy. In six women with Dunnigan-
type familial partial lipodystrophy (FPLD2), with hypoleptinemia (mean 3.8 ng/ml), 
dyslipidemia and diabetes, 0.08 mg/kg/d of r-metHuLeptin over 12 months induced 
moderate effects on weight loss (62.1 to 60.2 kg on average), with non-significant 
reductions in resting energy expenditure, percent body fat and liver volume [49]. 
Despite a decrease in fasting glycemia and an improvement in insulin sensitivity 
(assessed by the insulin tolerance test, ITT), HbA1c remained elevated (8.4 to 8%, 
non significant). Oral glucose tolerance tests showed that impaired glucose tolerance 
and insulin response were not improved by the treatment. These disappointing 
results could be due to depressed endogenous insulin secretion in these patients [49]. 
However, r-metHuLeptin was significantly efficient in reducing hypertriglyceridemia 
[49]. 
A patient with FPLD3 and low leptin levels due to PPARG mutation, was treated with 
r-metHuLeptin, with relatively high doses (up to 0.12 mg/kg/d) [50]. In contrast to 
results obtained in FPLD2, dramatic improvements in both glucose homeostasis and 
triglyceridemia were observed at 18 months, with increased insulin sensitivity 
(assessed by ITT) but also increased insulin secretion in response to an oral glucose 
tolerance test. Therefore, effects of r-metHuLeptin on "-cell function, which was only 
investigated during OGTT in rare studies, remains unclear. No improvement in insulin 
secretion was observed in six women with FPLD2 [49], in six patients with 
generalized lipoatrophy [36], and in five patients with congenital lipodystrophy due to 
seipin mutations [39]. In addition, as noted below, the severe fasting insulinopenia 
observed in two cases of acquired lipodystrophy associated with type 1 diabetes was 
not reversed by r-metHuLeptin, although an improvement in insulin sensitivity and a 
decrease in serum triglycerides and liver steatosis were observed [51]. However, 
insulin secretion was dramatically improved after r-metHuLeptin therapy at least in a 
patient with FPLD3 and in two patients with acquired generalized lipodystrophy [39]. 
Therefore, further studies are needed with precise metabolic investigations to know if 
r-metHuLeptin therapy is able to improve relatively preserved insulin secretion in 
lipodystrophic patients.  
 
Recently, the group of P. Gorden reported their 8-yr experience of r-metHuLeptin 
replacement therapy in 48 patients with acquired or inherited, generalized or partial 
lipodystrophies with metabolic alterations [31]. They confirmed the significant and 
sustained improvements in glycemic control and dyslipidemia. Some patients showed 
an apparent secondary refractoriness to r-metHuLeptin, which was thought to be 
caused by a non-compliance to treatment. Therapeutic doses have been adapted to 
the metabolic responses, and the maximal dose (0.24 mg/kg/d) was still less than 
previously used in obesity studies [4]. E Oral and J Chan collected the published 
clinical experience of r-metHuLeptin therapy in lipodystrophies not related to HIV 
infection [52]. Although all the trials were all open-labelled, it can be conclude, from 
over 100 patients treated, that r-metHuLeptin is generally safe and efficient in treating 
the metabolic complications of lipodystrophies, and that the degree of therapeutic 
response is related to the severity of metabolic abnormalities [52]. 
 
From these studies, and from unpublished experiences of other teams [53] including 
ours, it appears that the magnitude of the response to r-metHuLeptin is probably 
determined, in part, by the magnitude of fat loss (on average, treatment response are 
greater in patients with generalized lipoatrophy than in those with partial 
lipoatrophies), and by the magnitude of metabolic abnormalities at baseline (on 
average, treatment response are greater in patients with markedly elevated HbA1c 
and/or triglyceride levels at baseline).    
If r-metHuLeptin is very well-tolerated, its immune modulatory effects remains a 
subject of concerns since it could, in theory, exacerbate auto-immune conditions, 
frequently associated with acquired forms of lipodystrophy, and/or induce a 
secondary resistance to treatment due to the appearance of anti leptin antibodies. In 
addition, two cases of T cell lymphomas were described under r-metHuLeptin 
replacement therapy. Even if proliferative lymphoid cells disorders can be associated 
with acquired forms of lipodystrophy in the absence of leptin therapy [40] and 
personal observations], it is unknown if r-metHuLeptin could have played a promoting 
role in these two cases. 
 
 
1.2.2 Lipodystrophic syndromes linked to HIV infection and/or antiretroviral treatment  
 
HIV-associated lipodystrophic syndrome is a collective term for a very heterogeneous 
set of conditions frequently observed in, and unique to, HIV-infected patients 
receiving antiretroviral therapy. Briefly, the clinical presentation of HIV-associated 
lipodystrophic syndrome varies from generalized lipoatrophy to “lipohypertrophy” 
(with buffalo humps and abdominal obesity), with mixed, intermediate forms in 
between that resemble partial lipodystrophies. The severity of metabolic 
complications (i.e. dyslipidemia, insulin resistance with altered glucose tolerance, 
liver steatosis, cardiovascular diseases) is also highly variable from one form to 
another, and from one patient to another [54].  
 
Pathophysiological mechanisms of HIV-associated lipodystrophic syndromes are 
also complex, multiple, and incompletely deciphered. Generally, it seems that the 
previously used antiretroviral treatments, particularly nucleoside reverse 
transcriptase inhibitors such as stavudine or zidovudine, had the potential to induce 
severe lipoatrophy that only partially reversed after switching to newer agents. These 
treatments are not used anymore in industrialized countries and the incidence of the 
more severe forms of lipoatrophies has decreased, whereas partial lipodystrophies 
with abdominal and/or cervical accumulation of fat and metabolic complications 
develop still frequently. Other factors, like the use some HIV protease inhibitors or 
other classes of antiretroviral therapies, but also virally-mediated mechanisms as 
immune deficiency and low grade inflammatory state, the responses to the therapies, 
and the aging process, could interfere with adipose tissue distribution, insulin 
sensitivity and lipid metabolism [54,55]. 
 
In contrast to the rare (genetic, idiopathic, or auto-immune-related) forms of 
lipodystrophy in which a marked and sustained effect of r-metHuLeptin has been well 
documented in long-term studies, it is presently unknown whether r-metHuLeptin 
may also have significant long-term therapeutic potential in HIV-associated 
lipodystrophic syndrome. Indeed, three short-term trials of r-metHuLeptin therapy in 
patients with HIV-associated lipodystrophy with low leptin levels and 
hypertriglyceridemia at baseline have provided mixed results [56-58].  
In the first study from the group of Mantzoros [56], seven HIV-infected men with 
highly active antiretroviral therapy (HAART)-associated lipoatrophy, hypoleptinemia 
(< 3 ng/ml) and moderate hypertriglyceridemia, were treated by r-metHuLeptin (with 
low doses, i.e. 0.04 mg/kg/d) for two months through a placebo-controlled crossover 
study. Interestingly, despite a 1 month ! or a 2 month- therapy, two subjects were 
withdrawn from the study due to hypertriglyceridemia, reaching values greater than 
1000 mg/dl. Multivariate statistical analysis showed that this short-term r-
metHuLeptin therapy significantly decreased body fat, mainly due to a decline in 
trunk fat, and tended to decrease, independently to other factors, insulinemia and the 
insulin resistance index HOMA-IR (p= 0.07 and 0.06, respectively). R-metHuLeptin 
also increased HDL-cholesterol levels, at least partially through the decrease in 
visceral fat mass. R-metHuLeptin was well-tolerated, without any side effects, and 
without any alteration in HIV control, but had no significant effect on liver volume, 
percentage of liver fat, blood pressure, inflammatory markers (CRP, IL6, TNF#), 
serum adiponectin, fasting glucose or triglycerides. The insulin-like growth hormone 
(IGF) axis (i.e. serum IGF1, IGF2, IGF-binding proteins 1 to 4) was not altered by the 
therapy [59]. 
Another study directed by CS. Mantzoros [58] studied the therapeutic combination of 
pioglitazone and r-metHuLeptin in HIV-infected lipoatrophic hypoleptinemic patients. 
Five patients receiving the combination therapy were compared to four patients 
treated by pioglitazone alone, in a double-blinded fashion. R-metHuLeptin therapy, 
administrated for 3 months at a 0.04 mg/kg/d dose, significantly reduced fasting 
insulinemia and HOMA-IR, as well as postprandial glycemia, and increased serum 
adiponectin, but did not affect body mass index, body fat mass and distribution, or 
serum lipid profile. 
Mulligan et al [57] performed an open-label, 6-month pilot study of r-metHuLeptin 
treatment, at 0.02 then 0.06 mg/kg/d, in eight HIV-infected men with the same 
inclusion criteria (lipoatrophy, hypoleptinemia, moderate hypertriglyceridemia). 
Visceral fat significantly decreased after 6 months of therapy (on average, - 32%), 
with decrease in the trunk-to-limb fat ratio, and loss of body weight (-2 kg on 
average). Fasting total, LDL-cholesterol and triglycerides decreased. Metabolic 
investigations, with euglycemic hyperinsulinemic clamps and stable isotope tracer 
studies, showed that r-metHuLeptin improved the ability of insulin to suppress both 
endogenous hepatic glucose production (by decreasing both glycogenolysis and 
gluconeogenesis) and adipose tissue lipolysis (as assessed by a decrease in serum 
free fatty acids). However, skeletal muscle insulin sensitivity (evaluated by the 
insulin-mediated whole-body glucose uptake) was not significantly improved by r-
metHuLeptin therapy. 
 
Taken together, these trials, which included only a few patients (a total of less than 
25 patients) with HIV-associated lipoatrophy, consistently showed that r-metHuLeptin  
did not aggravate lipoatrophy, and improved hepatic insulin sensitivity. A significant 
decrease in hypertriglyceridemia was observed in only one study, using a longer 
duration and higher doses of r-metHuLeptin than the two other trials. The effects of r-
metHuLeptin in the most frequent forms of HIV-associated lipodystrophy, i.e. the 
mixed or lipohypertrophic forms are still unknown. Larger studies are needed to 
evaluate the long term effect of r-metHuLeptin in HIV-associated lipodystrophic 
syndromes.   
 
 
1.3 Hypothalamic amenorrhea  
 
Hypothalamic amenorrhea is due to dysfunction of the hypothalamic-pituitary-
gonadal axis in the absence of organic disease. Its clinical spectrum ranges from 
hormonal abnormalities in strenuously exercising athletes to anorexia nervosa. 
Affected subjects are hypoleptinemic, which might contribute to neuroendocrine 
dysfunctions with subsequent anovulation in women, and osteoporosis. In an open- 
label interventional study [60], three months of r-metHuLeptin treatment with 
replacement doses in women with amenorrhea improved or normalized the gonadal, 
thyroid and, to a less degree, growth hormone axes. A recent extension of this pilot 
study confirmed these results. A randomized double blinded placebo-controlled trial 
[61] of r-metHuLeptin with replacement doses (0.04 to 0.12 mg/kg/d) over 36 weeks, 
in 20 women with amenorrhea for a mean duration of 4 or 5 years, showed that r-
metHuLeptin therapy resulted in recovery of menstruation (7 of 10 patients), and 
corrected the abnormalities of the gonadal, thyroid and adrenal axes. However r-
metHuLeptin also induced a progressive loss of total body fat mass (of about 2 kg of 
fat on average), without changes in patients’ exercise patterns and eating habits.  
Those results are very encouraging for the treatment hypothalamic amenorrhea and 
the perspective of pregnancy for these patients. However, the risk of weight loss has 
to be considered, and further studies should be performed to look forward the long-
term safety of this therapeutic approach. 
 
As far as bone remodeling is concerned, short-term r-metHuLeptin therapy in these 
women has been shown to increase circulating levels of bone formation markers [60]. 
A long-term r-metHuLeptin treatment also showed an increase in bone mineral 
density and content at the lumbar spine level [62]. However, these effects, which 
have not been observed in other cases of r-metHuLeptin therapy, could have been 
linked to other neuroendocrine improvements. Before r-metHuLeptin could be 
proposed for the treatment of osteoporosis, more studies are required to elucidate 
the mechanisms underlying the effects of leptin on bone remodelling in humans. 
 
 
2- Leptin therapy in common obesity  
 
The discovery of leptin in 1994 [1] generated great hopes for the treatment of 
common obesity. However, subsequent clinical trials using pharmacological doses of 
r-metHuLeptin were disappointing, showing a very limited effect in inducing weight 
loss in obese patients [4]. Indeed, the vast majority of obese humans have high 
circulating leptin levels and are either resistant or tolerant to its weight-reducing 
effects [63]. The precise mechanisms underlying leptin resistance or tolerance in 
obesity are still not fully understood.  
Recent studies suggested that leptin sensitivity is directly related to endoplasmic 
reticulum (ER) capacity: ER stress blocks leptin action and generates leptin 
resistance in mice, suggesting that ER stress provides a potential mechanism for the 
development of leptin resistance [64]. This data has been recently confirmed in 
human primary adipocytes in vitro [65], indicating that ER stress may also induce 
leptin resistance in humans [66] and suggesting that improving ER stress could be 
used as a strategy to sensitize not only obese mice but also humans to leptin.  
 
Strategies to address leptin resistance in common obesity have included the use of 
high pharmacological doses of r-metHuLeptin, and/or its coadministration with 
presumed leptin sensitizers. 
An early trial with high doses of r-metHuLeptin (up to 0.3mg/kg/d) resulted in a weight 
loss which was non significant after 24 weeks of treatment. Indeed, there was 
considerable variability in the amount of weight lost by individual subjects (mean 
"7.1kg; SD 8.5) [4]. Moreover, these doses induced skin irritation and swelling at the 
injection site in 62% of patients and headache in half of the patients.  
In a recent double-blinded, placebo–controlled, randomized trial, r-metHuLeptin 
administration at a dose of 10 mg twice daily (20 mg/d) for 16 weeks did not alter 
body weight or circulating inflammatory markers in obese patients with type 2 
diabetes [65]. In this trial, r-metHuLeptin therapy was associated with an increased 
leptin binding protein that may decrease circulating free leptin levels.    
 
Recently, amylin, a hormone secreted by the pancreas that also contributes to the 
regulation of energy homeostasis through hindbrain signals of short-term satiety, was 
proposed to improve r-metHuLeptin responsiveness in diet-induced obesity [67]. A 
recent double-blinded randomized study conducted by Amylin Pharmaceuticals, Inc. 
found that overweight and obese participants lost significantly more weight on the 
combination of r-metHuLeptin and pramlintide, an analog of amylin (mean weight 
loss of 12.7%), than on treatment with either agent alone (mean 8.2% for r-
metHuLeptin and 8.4% for pramlintide) [68]. This weight loss corresponds to 67 % (± 
4%) of patients’ excess body weight by week 20 (mean initial BMI=32 kg/m2). The 
greater reduction in body weight was significant as early as week 4, and weight loss 
continued throughout the 24 weeks of treatment, without evidence of a plateau and 
with a good tolerance.  
Despite those very promising weight-loss results and improvements in metabolic 
markers in overweight and mildly obese subjects, progress in the development of 
pramlintide/r-metHuLeptin combination therapy has since stalled, with Amylin 
Pharmaceuticals and Takeda Pharmaceuticals stating on 16th March 2011 that the 
“clinical study was voluntarily halted to investigate a new antibody-related laboratory 
finding with metreleptin treatment in two patients who participated in a previously 
completed clinical study of obesity” (Press Release, Amylin and Takeda Voluntarily 
Suspend Clinical Activities in Obesity Trial, 3/16/11). These findings need to be fully 
resolved before further development of recombinant human leptin, because antibody 
formation in that study was observed with or without combination of amylin. 
 
A more promising area of clinical interest is the potential role of r-metHuLeptin 
treatment in weight loss maintenance. It has been proposed that falling leptin levels 
due to weight loss activate neuroendocrine mechanisms that may drive patients to 
regain weight. These mechanisms may include increasing energy intake, by 
increasing hunger, and decreasing energy expenditure, by decreasing thyroid 
hormone levels and subsequently slowing metabolism [69]. Thus, r-metHuLeptin 
therapy may avoid these neuroendocrine deleterious responses and prevent “yo-yo” 
dieting commonly seen in clinical practice. This is currently being investigated and, if 
successful, may have major implications in weight loss management. 
 
 
3- Leptin and diabetes 
 
3.1 Type 1 diabetes 
 
If the intensification of insulin treatment in type 1 diabetes reduced in a major way the 
degenerative complications by improving blood sugar control, it does not restore the 
metabolic homeostasis compromised by the destruction of the beta- pancreatic islets. 
Several studies in insulin-deficient rodents suggested that the administration of leptin 
could treat type 1 diabetes or improve the effect of insulin therapy [70-73], and has a 
more favorable effect than insulin on lipid and cholesterol metabolism. These effects 
were not only connected to the appetite-suppressing effect of leptin. Indeed, it has 
been shown that leptin, in an insulin and nutrition-independent manner, decreased 
the hepatic glucose output and increased the peripheral glucose utilization [70]. In 
addition, leptin inhibits the oversecretion of glucagon associated with insulin 
deficiency, stimulates insulin signaling, activates the muscular IGF1 receptor [72], 
and reduces the amount of liver triglycerides [73] in insulin-deficient animals. A 
recent study evidenced that high doses of leptin could also modulate the autoreactive 
destruction of beta cells in a virally induced rodent model of type 1 diabetes, and 
prevent hyperglycaemia [74].  
The dramatic reduction in adipose tissue observed in animal models of insulin-
deficient diabetes makes a good rational for restoring leptin levels as in lipoatrophic 
models. Thus, what would be the effect of r-metHuLeptin treatment in type 1 diabetes 
in humans? 
 
Only one study has reported the effects of r-metHuLeptin therapy in two patients with 
type 1 diabetes associated with acquired lipodystrophy, which represents an 
increased risk for autoimmune disorders [51]. R-metHuLeptin (0.08 mg/kg/d) 
improved the glycaemic control, allowing a decrease in the insulin requirements (3.3–
5 U/kg/d to 1 U/kg/d), and lowered circulating triglycerides and liver enzymes after 12 
months of therapy. This study showed that r-metHuLeptin reduced insulin resistance 
and ectopic fat in these patients but had no effect on fasting insulin levels [51].  
 
A phase 1 Interventional study is now running to study the effects of r-metHuLeptin 
administration in Patients with Type 1 Diabetes Mellitus and will ended in 2013 
(Principal investigator: A. Garg, Ut Southwestern Medical Center).  
 
 
3.2 Type 2 diabetes 
 
Type 2 diabetes occurs mainly in subjects with centrally-distributed fat accumulation 
and is characterized by a decrease in insulin action and a insulin secretory defect. A 
mouse model mimicking human type 2 diabetes with increased adiposity using low-
dose streptozotocin, a toxic pancreatic beta cell drug, and high-fat diet has been 
treated with recombinant mouse leptin for 14 days using a mini-osmotic pump [75]. 
Continuous leptin infusion reduced food intake, body weight and insulin resistance. It 
improved glucose and lipid metabolism! independently of the food intake reduction 
and it reduced liver and skeletal muscle triacylglycerol contents. In order to 
circumvent peripheral leptin resistance in models of obesity and type 2 diabetes, 
application of one time central leptin gene therapy to enhance leptin supply locally in 
the hypothalamus, has been proposed and offers an efficient and durable antidiabetic 
effect (review in [76]). However its implementation in humans is not possible in the 
next future.  
The effects of r-metHuLeptin therapy have been evaluated in obese subjects with 
type 2 diabetes in a double-blinded, placebo–controlled, randomized trial [65], 
Subjects were hyperleptinaemic. As mentioned in the paragraph 2., the treatment did 
not affect body composition. After 16 weeks of treatment, r-metHuLeptin reduced 
HbA1c marginally but significantly, by 0.1-0.2 %. Long term trials are needed to 
better evaluate whether r-metHuLeptin therapy may be useful in the therapeutic 
strategy of type 2 diabetes.  
 
 
3.3 Diabetes due to extreme insulin resistance  
 
The Rabson-Mendenhall syndrome is one of the most severe forms of insulin 
resistance, caused by a mutation affecting both alleles of the insulin receptor gene 
[77]. As the administration of r-metHuLeptin has been shown to improve insulin 
stimulated hepatic and peripheral glucose metabolism in severely insulin resistant 
lipodystrophic patients, one study has evaluated r-metHuLeptin therapy in this 
syndrome of poor prognosis for which treatment options are very limited. 
 
A 11 yr-old girl and her 13 yr-old brother presenting with a phenotype consistent with 
the diagnosis of Rabson-Mendenhall syndrome, i.e. severe insulin resistance with 
acanthosis nigricans and diabetes, growth retardation, but normal triglyceridemia and 
no liver steatosis, were treated with r-metHuLeptin. Unfortunately, the genotype of 
these patients was not available. Their baseline leptin serum levels were appropriate 
for fat mass. R-metHuLeptin was administrated twice daily, in addition to their 
previous antidiabetic therapy, including metformin and rosiglitazone in both patients, 
and 300U of daily insulin in the male sibling. After gradual increase, the maximal r-
metHuLeptin administration doses were stable at 0.09 mg/kg/d for the female and 
0.06 mg/kg/d for the male patient, from the sixth month to the last month (10th 
month) of treatment [78].  
After 10 month of treatment, a 40-60% decrease in fasting serum glucose levels and 
a 15% decrease in HbA1c were observed, concomitantly with a 30% reduction in 
insulin doses in the male sibling. Fasting insulinemia, which was extremely high at 
baseline (194 to 268 U/ml), was reduced by 80% in the female patient, who was not 
treated with exogenous insulin, and glucose levels decreased by 40% as compared 
with the pretherapeutic levels during insulin tolerance tests, showing that the 
pharmacological doses of r-metHuLeptin had improved insulin sensitivity. R-
metHuLeptin induced a 11% reduction in the mean caloric intake, resulting in a 
modest loss of fat mass, with lean body mass and resting energy expenditure 
remaining stable. All these metabolic effects were reversed after treatment 
withdrawal. Importantly, r-metHuLeptin therapy did not impair the growth and 
development of the siblings, and did not induce puberty in the prepubertal sister, 
consistent with the permissive effect of leptin on gonadotrophin secretion once 
puberty occurs only [78]. Long-term effects of r-metHuLeptin have not been reported 
in these children. 
 
4- Other indications for recombinant human leptin therapy? 
 
4.1 Obesity with low leptin serum level  
 
Anthropometric studies were performed by Farooqi et al. in 13 heterozygous subjects 
with leptin inactivating mutations from the same family, compared to three carriers of 
the homozygous wild-type allele, and to 96 ethnically-matched controls [79]. 
Heterozygote carriers of leptin inactivating mutations had significantly lower leptin 
serum levels than expected for percent body fat, and higher percentage of body fat 
than predicted from their weight and height. These results suggest that, if increasing 
leptin levels above a minimal threshold did not significantly alter the energy balance 
in common obese patients, the sensitivity to serum leptin changes in the low range 
values could have interesting therapeutic effect in obese subjects with relatively low 
levels of circulating leptin [79]. However, results of r-metHuLeptin therapy trials in 
these patients are not available for the moment. 
 
4.2 Depression and dementia 
 
The article by Yamada et al. [80] challenges some conventional views of leptin with 
evidence that the lack of leptin action in the hippocampus is associated with 
depressive behaviour in mice. Human studies show links between depression, 
adiposity, and proinflammatory states [81], and a recent study of r-metHuLeptin 
replacement therapy in three patients showed in vivo evidence of remarkably plastic, 
reversible and regional specific effects of leptin on human brain morphology 
(assessed by MRI), affecting in particular the gray matter concentration in areas 
involved in food intake [82].  
 
Regarding dementia, several studies in cells and in mice suggest that leptin could be 
protective against Alzheimer disease, in particular through activation of AMPK and 
the sirtuins, leading to a reduction in the phosphorylation of protein tau and the 
production of " amyloid substance in neurons [83,84]. In humans, some reports have 
shown a negative correlation between circulating leptin levels and risk of Alzheimer 
disease [85,86] or cognitive decline [87]. Interestingly, a longitudinal study of 785 
cognitively-normal persons with a mean age of 79 showed that higher circulating 
levels of leptin were associated with a reduced incidence of dementia and Alzheimer 
disease, during a median follow-up of 8.3 years [88]. Taken together, these data 
open favorably the way for clinical trials of recombinant human leptin as a novel 
therapy for Alzheimer dementia [89]. 
 Conclusion 
 
Administering r-metHuLeptin to correct overt hypoleptinemia significantly improves 
the metabolic abnormalities in patients bearing inactivating mutations in the leptin 
gene or lipodystrophic syndromes. R-metHuLeptin therapy have shown significant, 
albeit less pronounced effect in hypoleptinemic patients with human 
immunodeficiency virus–induced lipodystrophy and metabolic syndrome. In contrast, 
obese hyperleptinemic subjects with or without type 2 diabetes do not respond to 
exogenously administered r-metHuLeptin.  
Although r-metHuLeptin allows important metabolic improvements in patients with 
lipodystrophic syndromes, it is not widely available for the moment. In Europe, the 
pharmaceutical firm Amylin (San Diego, CA, USA) supports several compassionate 
programs. This restricted access is an important limit to its clinical use, and, if an 
expanded FDA-authorized access program is developed in USA, its approval as an 
orphan drug in Europe is urgently needed. 
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